

Clinical pharmacology: Now, More than Ever!

Eastern
European Time
(EET)

Saturday June 25 2022

13:00

Pre-meeting for
Young Clinical Pharmacologists

13:00-13:10

Introduction by **Carla Sans and Émilie Jouanjus**

13:10-13:30

Updates on the collaborative research project on medical cannabis conducted by Young Clinical Pharmacologists by **Émilie Jouanjus**

13:30-13:50

"Research and mobility support for Young Clinical Pharmacologists" - current resources and future wish list by **Carla Sans**

13:50 - 14:00

Break

14:00 - 14:40

"Speed pharmacology dating" among Young Clinical Pharmacologists

14:40 - 14:50

Coffe break and networking

14:50 - 15:50

www.prescribingeducation.eu (Presentation of the platform, Q&A, and discussion about needs and ideas of future contributions) by **Erik Donker and Chiel Bakkum**

15:50 - 16:00

Conclusion by **Carla Sans and Émilie Jouanjus**

Sunday June 26 2022

SKALKOTAS HALL

09:00	Welcome and introduction; "Clinical pharmacology; Now, more than ever!" by Vangelis Manolopoulos, president of the local organizing committee and Pierre Marquet, EACPT president		
09:20	Plenary lecture #1: "Hepatic adverse drug reactions to antimicrobials: predictable?" by Ann K. Daly Chairs: Vangelis Manolopoulos, Jamie Coleman, Pierre Marquet		
10:00	Refreshment break		

SKALKOTAS HALL

10:40	Plenary lecture #2: "Regulation at Speed" by Marco Cavaleri		
11:20	Lifetime achievement award and lecture by Kim Brosen Chairs: Vangelis Manolopoulos, Jamie Coleman, Pierre Marquet		
12:00	Lunch break		

13:00	Poster Presentations		
-------	----------------------	--	--

	MC3	SKALKOTAS HALL	MC2
--	-----	----------------	-----

14:00	S1a: Pharmacogenomics in clinical practice (co-organized with ESPT, European Society of Pharmacogenomics and Personalized Therapy) Chairs: Vangelis Monolopoulos, Julia Stingl	S1b: Immunopharmacology Chairs: Annalisa Capuano, Ioanna Andreadou	S1c: COVID-19 Update on therapies Chairs: Miia Turpeinen, Josep Maria Miro
-------	--	--	--

	Speaker 1: Adrian Llerena Pharmacogenetics clinical Implementation in European Health Services: Examples from Spain	Speaker 1: Xiaoli Meng Role of immunology/hypersensitivity in drug toxicity	Speaker 1: Roger Paredes Treatment
	Speaker 2: Mikko Niemi Pharmacogenomics of cholesterol-lowering therapy – implementation into clinical practice and future perspectives	Speaker 2: Liberata Sportiello Immune checkpoint inhibitors (ICIs) and immune-related adverse drug reactions: focus on their neurotoxicity	Speaker 2: César Sanz Prophylaxis (mRNA vaccines)
14:54-15:07	196 - Qinglian Zhai Added value of DPYD whole exon sequencing to explain severe fluoropyrimidine-induced toxicity	14:54-15:07 233 - Kenza Abouir Impact of obesity on dexamethasone pharmacokinetic in COVID-19 hospitalized patients: an observational exploratory study	14:54-15:07 70 - Roos Sablerolles Immunogenicity 5-months after homologous or heterologous booster vaccination in Health Care Workers primed with Ad26.COV2.S
15:07-15:20	11 - Camille Lenoir Impact of the genotype and phenotype of CYP3A and P-GP on the apixaban and rivaroxaban blood concentrations in real-world setting	15:07-15:20 238 - Clarisse Brossier Intestinal permeability in transplant patients: are systemic short-chain fatty acids an early biomarker?	15:07-15:20 76 - Vânia Rocha Geographic variation in top-10 prescribed medication and potentially inappropriate prescription in Portugal: an ecological study of 2.2 million older adults
15:20-15:33	208 - Georgia Ragia Direct oral anticoagulant-related bleeding in atrial fibrillation patients alters DNA methylation of NOS3 and KDR genes		15:20-15:33 66 - Simon Dedroogh SARS-CoV-2-Antibodies after different VaccineCombinations in hospital staff (HelCo-Vac Study)

15:30	Refreshment break		
-------	-------------------	--	--

15:40	S2a: OMICS and Targeted Biomarkers Chairs: Ann Daly, Arantxa Sancho Lopez	S2b: Joint meeting with IUPHAR Chairs: Ingolf Cascorbi, Pierre Marquet	S2c: Mixed Oral Presentations (1) Chairs: Michiel Van Agtmael, Pau Acubilla
-------	---	--	---

	Speaker 1: Prof Maribel Lucena Drug induced liver diseases	Speaker 1: Ingolf Cascorbi IUPHAR – Chances of international cooperations of pharmacological societies	15:40-15:53 97 - Haithem Chtioui Safety, tolerability and pharmacokinetic profile of Macozinone (PBTZ169) formulated as native crystal powder: multiple ascending-doses, phase-Ib trial in healthy volunteers
	Speaker 2: Gerd-Achim Kullak-Ublick New biomarkers	Speaker 2: Michael Spedding Challenges of drug development in Covid-19	15:53-16:06 260 - Alina Kasimova The use of screening data for the carrier of multi-resistant microorganisms to determine strategies for antibiotic prophylaxis and treatment
16:34-16:47	54 - Areti-Maria Vasiliogianni Quantitative Proteomics of Hepatic Drug-Metabolizing Enzymes and Transporters in Patients with Colorectal Cancer Liver Metastasis	Speaker 3: Caroline Samer The Clinical and Translational Section – Link to WHO	16:06-16:19 219 - Laura Aurinsalo Safety and applicability of a phenotyping cocktail of seven cytochrome P450 -selective substrate drugs for clinical trials
16:47-17:00	231 - Fani Koutsogianni Pharmacological characterization of a novel lipid-rich breast cancer patient-derived xenograft		16:19-16:32 133 - Jenny Dimakos Peptidomimetic structure of dipeptidyl peptidase-4 inhibitors and the risk of sulfonyleurea-induced severe hypoglycemia: a population-based cohort study
			16:32-16:45 96 - Sophie Fedrizzi Multiple sclerosis drugs and dental and gingival disorders: an observational retrospective study and disproportionality analysis in the world pharmacovigilance database

17:10	Shimadzu Symposium: "Innovative LC-MS/MS approaches for TDM" Prof. Franck Saint-Marcoux	IUPHAR Executives' Meeting	Round-table: European training in drug-drug interaction assessment: a comprehensive approach Dr Béatrice Saint-Salvi, Dr Caroline Samer
-------	--	-----------------------------------	--

18:30	WELCOME CEREMONY & RECEPTION		
20:00			

Monday June 27 2022

07:00	EACPT run		
08:00	Workshop 1: Debate session: Human challenge trials Chairs: David Webb, Joaquin Saez Speakers: Garth Rapeport and Susan Bull		Workshop 2: Happy Patient Project Chair: Jamie Coleman
08:50			
	MC3	SKALKOTAS HALL	MC2
09:00	S3a: Advanced Therapies Chairs: Arantxa Sancho Lopez, Georgios Papazisis	S3b: Clinical Pharmacology of cardiovascular drugs (joint meeting with EP HAR) Chairs: Ioanna Andreadou, Andreas Papapetropoulos	S3c: New ways of learning Clinical pharmacology Chairs: Michiel Van Agtmael, Jamie Coleman
	Speaker 1: Concepción Payares ORTHO UNION. An European, multinational experience Speaker 2: Sara Varea Hospital exemption: The happy end of the journey	Speaker 1: John Parisis SGLT-2 inhibitors in heart failure Speaker 2 : Gemma Vilahur Antithrombotic therapy in diabetes	9:00-9:15 Rowan Sultan Interprofessional learning 9:15-9:30 Jamie Coleman Discussion on the table and with the audience 9:30-9:50 Rashudy Mahomedradja & Jamie Coleman Debate: Learning medication reviews is useful
9:50-10:03	134 - Pooja Gupta Association of CYP2C19 Polymorphism with Treatment Response Among Multiple Myeloma Patients on Bortezomib Based Induction Treatment	9:50-10:03 5 - Guillaume Grenet SGLT2 inhibitors in diabetes, a systematic review and meta-analysis of cardiovascular outcome trials balancing their benefits against their risks	
10:03-10:16	71 - Woo Kyung Chung Pharmacokinetics and safety of DWJ211, injectable deoxycholic acid, after subcutaneous administration in healthy Korean subjects	10:03-10:16 170 - Iordanis Mourouzis Effects of acute triiodothyronine treatment in patients with anterior myocardial infarction undergoing primary angioplasty. Evidence from a pilot randomized trial	9:50-10:00 All Discussion on the table and with the audience and speakers
10:16-10:29	109 - Antonio F Caballero-Bermejo Multidisciplinary collaboration to address the urgent medical need of patients with severe COVID-19 ARDS: COVID-AT Study	10:16-10:29 235 - Jameela Bahar Characterising disease and prescribing patterns in patients with heart failure and multimorbidity: a single-centre descriptive cohort study	10:00-10:10 57 - Michael Reumerman "An inter-professional student-run medication review programme. Reducing adverse drug reactions in a memory outpatient clinic: A controlled clinical trial " 10:10-10:20 56 - Michael Reumerman An inter-professional student-run medication review programme: The clinical outcomes of a clinical controlled trial in a geriatric outpatient clinic 10:20-10:30 127 - Michiel Bakkum Novel teaching resources for the European Open Platform for Prescribing Education (EurOP2E) – a nominal group technique study
10:30	Refreshment break		
11:00	S4b: Mixed Oral Presentations (2) Chairs: Carla Sans, Emilie Jouanjus	S4a. Session organized by BPS: Clinical Prize Lectures Chairs: Reecha Sofiat, Vangelis Manolopoulos	S4c: CPT training across Europe Chairs: Jelle Tichelaar, Emelio Sanz
11:00-11:13	254 - Chryssa Pourzitaki Impact of OPRM1 and ABCB1 gene polymorphisms on the perioperative remifentanyl requirements and pain perception in patients undergoing elective thyroidectomy	Speaker 1: Richard Turner Pharmacogenomics v2.0 (BPS Dunlop Prize Lectureship 2021)	11:00-11:15 Erik Donker Europ2E a digital platform
11:13-11:26	132 - Jenny Dimakos Concomitant use of sulfonylureas and warfarin and the risk of severe hypoglycemia: a population-based cohort study	Speaker 2: Joel Tarning Pharmacological considerations in antimalarial treatments (Grahame-Smith Prize 2020)	11:15-11:30 Emilio Sanz Discussion on the table and with the audience
11:26-11:39	53 - Luz M Gonzalez Genetic variability in phospholipase genes affect nephrosclerosis risk and associated cardiovascular outcomes	Short talk 1: Lauren Walker Inclusivity and representation in clinical trial design	11:30-12:30 Chiel Bakkum Workshop Escaperoom
11:39-11:52	8 - Benjamin Skov Kaas-Hansen Eliciting drug safety signals from patient records: a language-agnostic approach	Short talk 2: Marie Fisk Sustainable medicines for planetary health	
11:52-12:05	257 - Natalia Atzemian Unraveling potential pharmacological target genes from transcriptomic profiles in the development of	Short talk 3: David Webb UK pharmacology contribution to Covid response, from drug development to regulation	
12:05-12:18	270 - Constantin Tamvakopoulos Therapeutic drug monitoring of anticancer monoclonal antibodies by mass spectrometry approaches		
12:30	Lunch / Poster Viewing		
13:00			
13:30			

Monday June 27 2022

SKALKOTAS HALL

14:00	Plenary Lecture #3: "Lessons learned from the COVID-19 pandemics" by Meletios A. Dimopoulos Chair: Pierre Marquet, Gerard Rongen, Vangelis Manolopoulos		
14:35	Plenary Lecture #4: "New Artificial intelligence tools to the service of medical questions" by Mihaela van der Schaar Chair: Pierre Marquet, Gerard Rongen, Vangelis Manolopoulos		
15:10	Refreshment break		
	MC3	SKALKOTAS HALL	MC2
15:30	S5a: Advanced Drug Delivery / Formulations Chairs: Janne Backman, Caridad Pontes	S5b: Systems Pharmacology and Artificial Intelligence in Clinical Pharmacology and Therapeutics (Joint session with ACCP) Chairs: Artemis Chatzigeorgiou, Julia Stingl	S5c: Changing the Benefit-Risk Balance of Medicines (challenging the mantra) Chairs: Arantxa Sancho Lopez, Pierre Marquet
16:50	Speaker 1: Giovanna Lollo Advanced nanomedicine for cancer immunotherapies : Challenges and opportunities Speaker 2: Giuseppe Curigliano Antibody-drug conjugates in solid tumors: will they hold the promise? Speaker 3: Robert Langer Micro-robots; Innovative Formulations	Speaker 1: Christian Lovis AI / machine Learning Speaker 2: Maria Giulia Bacalini Synthetic data generation, machine learning and Bayesian models for outcome prediction in drug development and personalized medicine Speaker 3: Don Mager Toward Application of Systems Analysis to Guide Decisions in Clinical Pharmacology and Therapeutics	Speaker 1: Ed Waddingham Changing the benefit-risk balance of medicines for patients – the joint mission of clinicians and regulators Speaker 2: Bahri Priya (EMA) New ways of appraising the benefit-risk balance 16:11-16:24 36 - Cathy Gaillard French academic and industrial experience on financial compensation of participants in clinical trials 16:24-16:37 130 - Pau Alcubilla Antineoplastic drug approvals by European Medicines Agency (EMA) and Food and Drug Administration (FDA) between 2018-2021. Evaluation of potential differences 16:37-16:50 202 - Lucía Arellano What has happened to medicines after a Conditional Marketing Authorisation (CMA) was granted by European Medicines Agency (EMA) from 2006-2020
17:00	Poster Viewing		EACPT Council Meeting
18:30			
19:30	Congress Dinner		
23:30			

Tuesday June 28 2022				
	MC3	SKALKOTAS HALL		MC2
08:00	Workshop 3: Pharmacovigilance in Practice (Greek Society of Pharmacology) Chair: Georgios Papazisis Speaker: Georgios Papazisis	Workshop 4: What makes a good journal peer review Chair: Julia Sting Speakers: Emilio Sanz and Ann Daly Interactive Workshop with true article examples and reviews		Workshop 5: Early access to innovative medicines Chairs: Arantxa Sancho Lopez, Caridad Pontes Speakers: Caridad Pontes and Montse Gasol
09:00	EACPT Executive Committee Meeting	Refreshment break		
10:00	S6a: Joint session with IATDMCT: TDM of mAbs Chairs: Dario Cataneo, Pierre Marquet Speaker 1: Dirck Jan Moes Model informed precision dosing of biologics: Challenges and opportunities Speaker 2: Joseph Ciccolini TDM of mAbs: is PK actionable?	S6b: Public-private collaboration in drug repurposing: challenges and opportunities Chairs: Gerard Rongen, George Kolios Speaker 1: Jan-Hein Cornelis Public-private collaboration in drug repurposing: challenges and opportunities Speaker 2: Ranganathah + Nick Sireau Collaboration of patients and scientists: Ongoing success story of OD for alkaptonuria		S6c: Special populations in drug-development and rational prescribing Chairs: Florian Naudet, Annalisa Capuana Speaker 1: Jean-Christophe Lega Use of race/ethnicity as population descriptors in pharmacology: benefits and challenges Speaker 2: Mario Braakman Cultural determinants of drug response
10:51-11:04	226 - Lieke Mitrov-Winkelmolen A retrospective study of anti-xa activity in patients with renal insufficiency receiving renal-based reduced or not-reduced therapeutic doses of dalteparin	10:51-11:04 210 - Imke Bartelink Pharmacokinetics and Pharmacodynamics for Optimal Drug Repurposing of Imatinib from Cancer to COVID-19	10:51-11:04	24 - Marie-Laure Laroche Applications of the REMEDI[e]S tool: implicit and explicit criteria for optimizing drug prescribing in older adults
11:04-11:17	194 - Niklas Kehl Development and validation of an LC-MS method for drug exposure measurement of 57 oral antitumor drugs in human plasma	11:04-11:17 14 - Kjolby Aarhus Repurposing the Japanese heartburn drug camostat to potential antiviral treatment in COVID-19 – a human trial.	11:04-11:17	155bis - Valentin Skryabin Effects of cyp3a4 genetic polymorphisms on the efficacy and safety profiles of diazepam in patients with alcohol withdrawal syndrome
11:17-11:30	99 - Rim Charfi Is there an association between valproic acid serum levels and remission in epileptic children?	11:17-11:30 23 - Patricia Rodríguez-Fortúnez Defibrotide in the prevention and treatment of acute respiratory distress syndrome in patients with COVID-19. Preliminary safety results update.	11:17-11:30	38 - Matthieu Roustit Placebo response in Raynaud’s Phenomenon clinical trials: the prominent role of regression towards the mean
11:30	EACPT General Assembly			
12:30	Lunch / Poster Viewing			
	Poster Presentations			
13:30	S7a: Mixed Oral Presentations (3) Chairs: Joaquin Saez, Vangelis Manolopoulos	S7b: Psychopharmacology Chairs: Georgios Papazisis, Mimi Stokke Opdal		S7c: Physiology-based pharmacokinetic modeling to guide personalized drug dosing Chairs: Gerard Rongen, Janne Backman
13:30-13:43	30 - Ji Yun Park Pharmacokinetics and pharmacodynamics of intravenous and oral fexuprazan, a potassium-competitive acid blocker, after single administration in healthy Korean and Chinese	Speaker 1: Emilie Jouanjus Pharmacological facts about cannabidiol		Speaker 1: Amin Rostami-Hodjegan On the verge of impossibility: caring for all permutations of comorbidities influencing fate of drugs
13:43-13:56	37 - Anna Teegelbekkers Effect of tacrolimus formulation (prolonged-release vs. immediate-release) on the extent of the pharmacokinetic interaction with St. John's wort	Speaker 2: Ingvild Odsbu Trends in use of prescribed opioids in Norway – should we be concerned?		Speaker 2: Rick Greupink Drug dosing during pregnancy and in children, how can PBPK modeling help?
13:56-14:07	108 - Antonio F Caballero-Bermejo Clinical characterization and prognosis outcomes of carbon monoxide poisoning in Spain. The AMICO study	14:24-14:37 129 - Debbie Zitterma Use of maximal urine concentrating capacity markers to evaluate lithium-induced nephrogenic diabetes insipidus	14:24-14:37	63 - Hyun Chul Kim Pharmacokinetics and pharmacodynamics of HIP1601, a novel dual delayed-release esomeprazole, compared to a conventional delayed-release esomeprazole in healthy male subjects
14:07-14:20	64 - Rostam Osanlou The identification of adverse drug reactions in medical hospital admissions: A one month prospective analysis	14:37-14:50 126 - Archana Mishra A randomized controlled trial to evaluate the effect of alpha lipoic acid in patients with treatment resistant schizophrenia	14:37-14:50	110 - Aaritz Landeta Manzano Evolution of 25(OH)D plasma levels in adults with hypovitaminosis D after a 4-month treatment with calcifediol: An interim analysis
14:20-14:33	80 - Anssi Mykkänen Comprehensive pharmacogenomics study of simvastatin pharmacokinetics: major role of SLCO1B1 and CYP3A4			
14:33-14:46	22 - Charles Khouri Risk of skin ulcer and use of cox-2 inhibitors: a national population-based nested case control study			
15:00	Presentation of Awards and Closing Ceremony			
16:00				